Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?

Key Takeaways Keytruda accounts for nearly 50% of MRK's pharma revenues, driving growth across cancer indications globally. Early-stage lung cancer and metastatic uptake are fueling strong sales momentum for Keytruda. Heavy reliance on Keytruda poses risks as the 2028 loss of exclusivity draws closer.Merck’s (MRK) primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts for almo ...